추천 제품
분석
≥97% (HPLC)
형태
solid
색상
white to off-white
solubility
DMSO: ≥5 mg/mL
주관자
Sanofi Aventis
저장 온도
2-8°C
SMILES string
Cl.FC(F)(F)c1cccc(c1)C2=CCN(CCc3ccc4ccccc4c3)CC2
InChI
1S/C24H22F3N.ClH/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18;/h1-9,11,16-17H,10,12-15H2;1H
InChI key
WVHBEIJGAINUBW-UHFFFAOYSA-N
유전자 정보
human ... HTR1A(3350)
생화학적/생리학적 작용
5-HT1A serotonin receptor agonist; neuroprotectant
특징 및 장점
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
신호어
Warning
유해 및 위험 성명서
예방조치 성명서
Hazard Classifications
Acute Tox. 4 Oral
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
개인 보호 장비
Eyeshields, Gloves, type N95 (US)
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials.
Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 5(2), 107-117 (2004-06-19)
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal motor neuron disease. We carried out two randomized, double-blind, placebo-controlled, multi-centre, multi-national studies with xaliproden (a drug with neurotrophic effect) to assess drug efficacy and safety at two doses. Patients
Journal of the neurological sciences, 160 Suppl 1, S92-S96 (1998-12-16)
SR57746A(1-[2-(naphth-2-yl)ethy]]-4-(3-trifluoromethyl phenyl)-1,2,5,6-tetrahydropyridine, hydrochloride) is a non-peptide compound which has been shown to exhibit a wide range of neurotrophic effects both in vitro and in vivo. Here we examine the ability of SR57746A on axotomized spinal motor neuron death in the
British journal of pharmacology, 158(1), 232-242 (2009-06-11)
Xaliproden (SR57746A) is a 5-HT(1A) receptor agonist and neurotrophic agent that reduces oxaliplatin-mediated neuropathy in clinical trials. The present study investigated its profile on in vitro transduction, neurochemical responses and acute nociceptive pain tests in rats. Xaliproden was tested on
Expert opinion on pharmacotherapy, 7(1), 1-10 (2005-12-24)
This review examines key pharmacological strategies that have been clinically studied for the primary or secondary prevention of Alzheimer's disease. Much information (neuropsychological, genetic and imaging) is already available to characterise an individual's risk for developing Alzheimer's disease. However, regulatory
Highlights From: the 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium San Francisco, CA, January 2006.
Clinical colorectal cancer, 5(6), 398-402 (2006-04-26)
문서
We offer many products related to serotonin receptors for your research needs.
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.